RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 159 filers reported holding RECURSION PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.85 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $59 | -46.4% | 7,868 | -29.0% | 0.00% | -100.0% |
| Q1 2024 | $110 | -5.2% | 11,082 | -5.8% | 0.00% | 0.0% |
| Q4 2023 | $116 | +1833.3% | 11,759 | +1508.6% | 0.00% | – |
| Q3 2023 | $6 | +20.0% | 731 | 0.0% | 0.00% | – |
| Q2 2023 | $5 | -91.1% | 731 | -91.3% | 0.00% | – |
| Q1 2023 | $56 | +5.7% | 8,411 | +21.8% | 0.00% | – |
| Q4 2022 | $53 | -99.2% | 6,903 | +1029.8% | 0.00% | – |
| Q3 2022 | $7,000 | -92.9% | 611 | -95.0% | 0.00% | -100.0% |
| Q2 2022 | $99,000 | +90.4% | 12,195 | +68.4% | 0.00% | – |
| Q1 2022 | $52,000 | -40.9% | 7,241 | +41.6% | 0.00% | -100.0% |
| Q4 2021 | $88,000 | – | 5,114 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kinnevik AB (publ) | 11,905,668 | $89,292,510 | 100.00% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $29,633,558 | 44.95% |
| Data Collective IV GP, LLC | 5,941,120 | $44,558,400 | 31.23% |
| NVIDIA CORP | 7,706,363 | $57,797,723 | 14.70% |
| MIC Capital Management UK LLP | 8,451,758 | $63,388,186 | 13.78% |
| ARK Investment Management | 28,142,918 | $211,071,885 | 1.87% |
| RA Capital Management | 15,384,615 | $115,384,613 | 1.53% |
| COMMONS CAPITAL, LLC | 111,107 | $833,302 | 1.00% |
| ELEVATUS WELATH MANAGEMENT | 342,567 | $2,569,253 | 0.96% |
| Lingotto Investment Management LLP | 3,675,077 | $27,563,078 | 0.93% |